5-Methyl-1-[6-(2-methylpyridin-3-yloxy)-pyridazin-3-ylcarbamoyl]-6-trifluoromethylindoline | 200940-25-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-Methyl-1-[6-(2-methylpyridin-3-yloxy)-pyridazin-3-ylcarbamoyl]-6-trifluoromethylindoline
• 英文别名: N-[6-(2-Methyl-3-pyridinyloxy)-3-pyridazinyl]-5-methyl-6-(trifluoromethyl)indoline-1-carboxamide；5-methyl-N-[6-(2-methylpyridin-3-yl)oxypyridazin-3-yl]-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide
• CAS: 200940-25-6
• 化学式: C₂₁H₁₈F₃N₅O₂
• 分子量: 429.401
• InChiKey: DIYDTCOAMMYNOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  31
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  80.2
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  3-羟基-2-甲基吡啶 在 sodium hydroxide 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 26.0h， 生成 5-Methyl-1-[6-(2-methylpyridin-3-yloxy)-pyridazin-3-ylcarbamoyl]-6-trifluoromethylindoline
  参考文献：
  名称：

  1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/Anxiolytic agents

  摘要：

  Bisaryl ethers have been identified with excellent 5-HT2C affinity and selectivity over both 5-HT2A and 5-HT2B receptors. Compounds such as 11, 27 and 38 have potent oral activity in a centrally mediated pharmacodynamic model of 5-HT2C function and their potential as novel non-sedating anxiolytic and antidepressants is under investigation. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00364-4

文献信息

• [EN] INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE L'INDOLINE UTILES COMME ANTAGONISTES DES RECEPTEURS 5HT-2C
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO1997048699A1

  公开（公告）日：1997-12-24

  (EN) The invention relates to heterocyclic compounds of formula (I) or a salt thereof wherein X is CH or N; R1 is hydrogen or C1-6 alkyl; R2 and R3 groups are independently halogen, C1-6 alkyl, or trifluoromethyl, having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders such as anxiety.(FR) L'invention concerne des composés hétérocycliques de formule (I), dans laquelle X est CH ou N; R1 est hydrogène ou alkyle C1-C6; et les groupes R2 et R3 sont indépendamment halogène, alkyle C1-C6 ou trifluorométhyle; et leurs sels; ces composés ayant une activité pharmacologique. L'invention concerne également des procédés permettant de les préparer et des compositions les contenant, ainsi que leur utilisation dans le traitement des troubles du système nerveux central tels que l'angoisse.

  该发明涉及公式（I）的杂环化合物或其盐，其中X为CH或N; R1为氢或C1-6烷基; R2和R3基团独立地为卤素，C1-6烷基或三氟甲基，具有药理活性，其制备过程，含有它们的组合物以及它们在治疗如焦虑症等中枢神经系统疾病中的用途。
• INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP0912554A1

  公开（公告）日：1999-05-06
• US6369060B1
  申请人：——

  公开号：US6369060B1

  公开（公告）日：2002-04-09
• 1-[2-[(Heteroaryloxy)heteroaryl]carbamoyl]indolines: novel and selective 5-HT2C receptor inverse agonists with potential as antidepressant/Anxiolytic agents
  作者：Steven M. Bromidge、Steven Dabbs、Susannah Davies、D.Malcolm Duckworth、Ian T. Forbes、Graham E. Jones、Jerome Jones、Frank D. King、Damian V. Saunders、Thomas P. Blackburn、Vicky Holland、Guy A. Kennett、Sean Lightowler、Derek N. Middlemiss、Graham J. Riley、Brenda Trail、Martyn D. Wood

  DOI：10.1016/s0960-894x(00)00364-4

  日期：2000.8

  Bisaryl ethers have been identified with excellent 5-HT2C affinity and selectivity over both 5-HT2A and 5-HT2B receptors. Compounds such as 11, 27 and 38 have potent oral activity in a centrally mediated pharmacodynamic model of 5-HT2C function and their potential as novel non-sedating anxiolytic and antidepressants is under investigation. (C) 2000 Elsevier Science Ltd. All rights reserved.